MALME-3M Cells

The MALME-3M cell line is a human melanoma model used extensively in cancer research to investigate mechanisms of melanoma progression, immune evasion, and drug resistance. This cell line is derived from a metastatic melanoma lesion and demonstrates several characteristics relevant to aggressive melanoma, including its ability to express key oncogenic markers such as HER2 and its role in modulating the tumor microenvironment. Studies involving MALME-3M have highlighted its responsiveness to targeted therapies, such as bispecific antibodies aimed at HER2, and its use in evaluating T-cell mediated immunotherapies.

One significant area of research involving MALME-3M cells is their utility in studying the mechanisms of immune evasion in melanoma. For instance, co-culture systems pairing MALME-3M with immune cells allow researchers to explore how melanoma cells modulate immune responses through pathways like PD-1/PD-L1 and other immune checkpoint inhibitors. This cell line has also been genetically modified to study the effects of gene perturbations on immune interactions, making it a valuable tool for high-throughput genetic screening.

In addition to its role in immunological studies, MALME-3M cells are instrumental in exploring the effects of growth hormone (GH) on melanoma progression. Research has demonstrated that GH can enhance drug resistance and metastatic potential in MALME-3M cells by altering the composition of melanoma-derived exosomes. These exosomes can transfer drug resistance and migration-promoting factors to other cells in the tumor microenvironment. Such studies underscore the potential of targeting GH signaling pathways as a therapeutic strategy for overcoming melanoma chemoresistance.